{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-118749","form_type":"8-K","ticker":"ACXP","cik":"0001736243","company_name":"Acurx Pharmaceuticals, Inc.","filed_at":"2023-11-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.262210+00:00","generated_at":"2026-06-08T02:37:30.248022+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Acurx Pharmaceuticals enters $17M ATM equity offering with A.G.P.","bullets":["Up to $17M of common stock may be sold from time to time in at-the-market offerings.","A.G.P./Alliance Global Partners acts as sales agent, receiving 3% of gross proceeds.","Sales may be made on Nasdaq Capital Market, OTC, or in negotiated transactions.","Company is not obligated to sell any shares under the agreement.","Offering made under existing Form S-3 shelf registration statement declared effective July 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-118749","json":"https://secwatch.observer/filing/0001104659-23-118749.json","markdown":"https://secwatch.observer/filing/0001104659-23-118749.md","text":"https://secwatch.observer/filing/0001104659-23-118749.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1736243/000110465923118749/0001104659-23-118749-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1736243/000110465923118749/tm2330856d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T02:37:30.248022+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"102051b86a10e1d9d155422f925249f3a153e8fa","claim":"Acurx Pharmaceuticals, Inc. entered into Sales Agreement with A.G.P./Alliance Global Partners valued at up to $17.0 million (effective 2023-11-15).","evidence_excerpt":"On November 15, 2023, Acurx Pharmaceuticals, Inc. (the “Company”) entered into a sales agreement (the “Sales Agreement” and such transactions contemplated thereby, the “ATM Program”) with A.G.P./Alliance Global Partners (the “Sales Agent”), pursuant to which the Company may offer and sell, from time to time, shares (the “Shares”) of its common stock, par value $0.001 per share (the “Common Stock”), having an aggregate offering price of up to $17.0 million through the Sales Agent, acting as agent.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1736243/000110465923118749/0001104659-23-118749-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"atm program"},{"label":"Counterparty","value":"A.G.P./Alliance Global Partners"},{"label":"Value","value":"up to $17.0 million"},{"label":"Effective","value":"2023-11-15"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}